Mammography Workstations Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product type (Multimodality Mammography Stations and Standalone Mammography Stations), By End-User (Hospitals, Diagnostic Laboratories, and Others), and By Region  

The mammography workstations market was valued at US$ 53.5 million in 2022 and is expanded to grow at a significant CAGR of 5.2% over 2023-2029. With the growing prevalence of breast cancer, technological advancements such as digital mammography, optical imaging, molecular breast imaging, electrical impedance, and tomosynthesis fuelled the global mammography workstations market. The continuous development and refinement of imaging systems and software can help lead to an early-stage diagnosis. Currently, most hospitals are shifting from 2D mammography systems to 3D mammography devices. In comparison with other available technologies on the market, 3D tomosynthesis has been identified as the fastest-growing for breast imaging, offering increased efficiency and higher diagnostic accuracy. For instance, At the recent 2018 Society for Breast Imaging (SBI)/American College of Radiology (ACR) Breast Imaging Symposium in Las Vegas, many current technologies were being showcased on the show floor. Hologic's Clarity HD high-resolution 3-D imaging and Intelligent 2-D imaging technology recently received FDA premarket approval (PMA) and are now available on the 3Dimensions breast tomosynthesis system. Hologic's Clarity HD high-resolution 3-D imaging and Intelligent 2-D imaging technology recently received FDA premarket approval (PMA) and are now available on the 3Dimensions breast tomosynthesis system. The segment's high market share is primarily due to the increased usage of these devices in hospitals and breast care centers. The multimodality workstation provides a high-resolution display and can compare two-dimensional display and tomosynthesis images.

Mammography Workstations Market Key Developments:

• In May 2021, GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients.
• In December 2020, Hologic Receives FDA Clearance for Latest Breakthrough in Early Breast Cancer Detection, Genius AI Detection.